Nyrada Inc – CEO Remuneration Update

Sydney, 27 October 2022: Nyrada Inc (ASX: NYR) (“Nyrada” or “the Company”) a preclinical stage, drug development company specialising in novel small molecule drugs to treat cardiovascular and neurological diseases, today advises of changes to the remuneration package for the Company’s Chief Executive Officer, Mr. James Bonnar.